Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics to meet unmet patient needs.
The company emphasizes forward-looking statements and highlights the importance of considering various risk factors outlined in its reports filed with the SEC.
Hoth Therapeutics aims to improve patient lives by translating complex science into practical treatments that enhance patient well-being.
Hoth Therapeutics' dedication to advancing early-stage drug candidates and its strong pipeline across various therapeutic areas demonstrate its potential to bring valuable treatments to patients in need.
Clinical Programs and Regulatory Paths
Hoth Therapeutics is advancing clinical programs with clear regulatory paths across oncology, neurology, dermatology, and inflammation, targeting large unmet patient needs in high-value markets.
Pipeline with Multiple Shots on Goal
The company's pipeline includes a range of drug candidates at different development stages, aiming to address diseases such as mastocytosis, KIT-driven cancers, Alzheimer's, atopic dermatitis, asthma, and obesity.
Lead Programs
Hoth Therapeutics' lead programs include HT-001, a topical gel that reduces skin toxicity from cancer therapies, and HT-KIT injection targeting rare mast cell diseases and KIT-driven cancers.
HT-001 Value Proposition
HT-001 addresses a widespread unmet need by reducing skin side effects in cancer therapy, improving comfort, and quality of life for patients.
HT-001 Milestones
The company expects favorable interim clinical data in Q1 2025, an EU trial expansion submission in Q3 2025, and a full PK dataset in Q1 2026 for HT-001.
- Hoth Therapeutics' focus on developing innovative therapeutics with the potential to address unmet patient needs underscores its commitment to improving patient outcomes.
- The company's strategic approach to translating complex science into practical treatments positions it well to make a significant impact in the clinical and consumer markets.
Hoth Therapeutics' dedication to advancing early-stage drug candidates and its strong pipeline across various therapeutic areas demonstrate its potential to bring valuable treatments to patients in need.